Bio-Rad Laboratories vs Revvity
BIO and RVTY side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIO and RVTY compare
Revvity is the larger company, worth 1.8 times as much as Bio-Rad Laboratories ($17.5B against $10.0B).
On earnings, Bio-Rad Laboratories is cheaper: it trades at 45.1× trailing earnings, against 74.8× for Revvity.
Revvity grew revenue faster over the last twelve months (4.1% versus 1.4% for Bio-Rad Laboratories).
Bio-Rad Laboratories keeps more of each dollar of sales as profit, with a net margin of 8.6% compared with 8.2% at Revvity.
Revvity pays a dividend yielding 0.13%; Bio-Rad Laboratories does not pay one.
Revvity scores higher on the StockData Score (11 against 8 for Bio-Rad Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIO | RVTY |
|---|---|---|
| Size and price | ||
| Market cap | $10.0B | $17.5B |
| Share price | $372.18 | $157.00 |
| Change, 1 year | 16.5% | 64.7% |
| Change, 5 years | −48.7% | −7.0% |
| Beta (5Y) | 1.04 | 1.03 |
| Employees | 7,450 | 11K |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 45.1× (better) | 74.8× |
| P/S | 3.8× (better) | 6.0× |
| P/B | 1.4× (better) | 2.4× |
| EV/EBITDA | 172× | 25.6× (better) |
| P/FCF | 28.2× (better) | 31.4× |
| FCF yield | 3.5% (better) | 3.2% |
| Fair value | $239.52 | $105.13 |
| Margin of safety | −55.4% | −49.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.4% | 4.1% (better) |
| Revenue growth, 5Y average | 0.29% | 1.4% (better) |
| Net income growth (TTM) | −30.3% | −16.7% (better) |
| EPS growth (TTM) | −29.7% | −11.0% (better) |
| EPS growth, 5Y average | −26.1% | −20.4% (better) |
| Profitability | ||
| Gross margin | 51.9% | – |
| Operating margin | 2.1% | 12.3% (better) |
| Net margin | 8.6% (better) | 8.2% |
| FCF margin | 13.6% | 19.2% (better) |
| Return on equity | 3.1% | 3.2% (better) |
| Return on invested capital | 0.51% | 3.4% (better) |
| Financial health | ||
| Debt / equity | 0.11 (better) | 0.44 |
| Net debt / EBITDA | −15.36 | 2.83 (better) |
| Interest coverage | 1.1× | 3.8× (better) |
| Current ratio | 3.14 (better) | 1.80 |
| Altman Z-score | 3.55 (better) | 3.34 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.13% |
| Payout ratio | – | 13.4% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | 1.3% | 2.7% (better) |
| Shareholder yield | 1.3% | 2.8% (better) |
| Ownership | ||
| Held by institutions | 83.2% | 102% |
| Held by insiders | 54.5% | 0.46% |
| Insider net buying, 12 months | −$350K (better) | −$6.0M |
| Short interest, % of float | – | 5.7% |
Go deeper
- BIO stock overview
- BIO income statement
- BIO valuation and score
- RVTY stock overview
- RVTY income statement
- RVTY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.